<DOC>
	<DOCNO>NCT00111189</DOCNO>
	<brief_summary>The purpose study evaluate efficacy paliperidone palmitate compare placebo prevention recurrence symptom schizophrenia assess safety tolerability paliperidone palmitate patient stable symptomatic schizophrenia . The placebo use study nutritional substance know 20 % Intralipid emulsion give patient require intravenous feeding .</brief_summary>
	<brief_title>A Study Efficacy ( Effectiveness ) Paliperidone Palmitate Prevention Recurrence Symptoms Schizophrenia .</brief_title>
	<detailed_description>Many patient schizophrenia difficulty adhere daily oral treatment regimen . Long-acting injectable formulation , long-acting injectable paliperidone palmitate , may provide therapeutic plasma concentration several week , thereby eliminate need daily oral medication make compliance easy . This study randomize ( patient assign different treatment group base solely chance ) , double-blind ( neither patient physician know placebo drug give dose ) , placebo-controlled , parallel-group , multicenter study follow open-label extension period patient schizophrenia . The study design evaluate efficacy paliperidone palmitate ( long-acting injectable formulation ) delaying time decrease rate recurrence compare placebo patient schizophrenia . The study consist 5 period : 7-day screening/washout/tolerability period , 9-week open-label transition period , 24-week open-label maintenance period , randomize , variable-length double-blind , placebo-controlled recurrence prevention period , 52-week open-label extension period . Patients intramuscular ( i.m . ) study drug injection efficacy safety evaluation perform every 4 week throughout study . Efficacy evaluate study use recurrence assessment , Positive Negative Symptom Scale Schizophrenia ( PANSS ) , Clinical Global Impression - Severity ( CGI-S ) scale , Personal Social Performance ( PSP ) scale . Safety assess throughout study monitor adverse event ; use extrapyramidal symptom ( EPS ) rating scale ( Abnormal Involuntary Movement Scale [ AIMS ] , Barnes Akathisia Rating Scale [ BARS ] , Simpson Angus Scale [ SAS ] ) ; clinical laboratory testing ; vital sign ( temperature , blood pressure , heart rate ) measurement ; electrocardiogram ( ECGs ) ; physical examination . Additionally , patient assess tolerability injection evaluate pain injection pain injection site . Tolerability test : 3 mg/day oral ER OROS paliperidone 4 day . Transition ( 9 wks ) : 50 mg eq . paliperidone palmitate i.m . dose Day 1 , i.m . injection ( 25 , 50 , 100 mg eq . ) every 4 wks ( q4wk ) . Maintenance ( 24-wks ) : paliperidone palmitate i.m . injection ( 25 , 50 , 100 mg eq . ) q4wk . Recurrence Prevention : paliperidone palmitate i.m . injection ( 25 , 50 , 100 mg eq . placebo ) q4wk . Open-label paliperidone palmitate ( 25 , 50 , 75 , 100 mg eq . ) q4wk 12 dose period .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patients meet diagnostic criterion schizophrenia accord DSMIVTM least 1 year screen PANSS score &lt; 120 body mass index ( BMI ) &gt; /=15.0 kilogram ( kg ) /meter ( ) 2 reside address least 30 day Patients unable provide consent involuntarily commit psychiatric hospitalization primary , active DSMIVTM diagnosis schizophrenia DSMIVTM diagnosis active substance dependence within 3 month screen ( nicotine caffeine exclusionary ) history treatment resistance define failure respond 2 adequate trial ( minimum 4 week therapeutic dose ) different antipsychotic medication history severe preexist gastrointestinal narrowing inability swallow medication whole water history neuroleptic malignant syndrome ( NMS ) significant risk suicidal violent behavior current presence significant unstable medication condition treatment protocol disallow therapy clinically significant result screen laboratory ECG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone palmitate</keyword>
	<keyword>R092670</keyword>
	<keyword>antipsychotic</keyword>
	<keyword>recurrence prevention</keyword>
</DOC>